Task sharing in an interprofessional medication management program – a survey of general practitioners and community pharmacists by Robert Moecker, Marina Weissenborn, Anja Klingenberg, Lucas Wirbka, Andreas Fuchs, Christiane Eickhoff, Uta Mueller, Martin Schulz, Petra Kaufmann-Kolle, ARMIN Study Group, Walter E. Haefeli, Hanna M. Seidling

“…Participants were asked who completed which MMP tasks, e.g., checking drug-drug interactions, dosing, and side effects. In total, 15 MMP tasks were surveyed using a 5-point Likert scale ranging from “I complete this task alone” to “GP/CP completes this task alone”. …”
Get full text

Combination therapy for bipolar disorder : What to combine and which cautions to take ? by M. Gardabbou, M. Maalej, R. Feki, I. Gassara, N. Smaoui, L. Zouari, J. Ben Thabet, S. Omri, N. Charfi, M. Maalej

“…Objectives To assess the place of non-pharmacological interventions as a co-adjuvant to pharmacological treatment, to discuss the role of polytherapy in the management of bipolar disorder and to underline the drug to drug interactions to keep in mind. Methods We present a critical review of recent international recommendations for the management of bipolar disorder. …”
Get full text

Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study by Delphine Sculier, Angèle Gayet-Ageron, Manuel Battegay, Matthias Cavassini, Jan Fehr, Cedric Hirzel, Patrick Schmid, Enos Bernasconi, Alexandra Calmy, for the Swiss HIV Cohort Study

“…It offers the advantages of few drug-drug interactions and a favourable toxicity profile. We aimed to determine the reasons for prescribing the rilpivirine (RPV)/tenofovir disoproxil (TDF)/emtricitabine (FTC) co-formulation within the Swiss HIV Cohort Study and to assess its effectiveness and safety over a 24 months period. …”
Get full text

Assessing the Impact of an Advanced Clinical Decision Support System on Medication Safety and Hospital Readmissions in an Innovative Transitional Care Model: A Pilot Study by Jennifer M. Bingham, Lindsey Baugham, Andriana Hilaneh, Karley Tranchina, Daniel Arku, Becka Eckert, Nicole Scovis, Jacques Turgeon

“…Overall, there were significantly more drug-drug interactions (DDI) MRPs identified per patient in the intervention vs. control group for those who were readmitted (3.7 ± 1.5 vs. 0.9 ± 0.6, <i>p</i> < 0.001) and those who were not readmitted (2 ± 1.3 vs. 1.3 ± 1.2, <i>p</i> = 0.0120). …”
Get full text

Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence by Pierluigi Viale, Christian E. Sandrock, Paula Ramirez, Gian Maria Rossolini, Thomas P. Lodise

“…Phase 1 studies established that cefiderocol achieves adequate concentration in the epithelial lining fluid in the lung and requires dosing adjustment for renal function, including patients with augmented renal clearance and continuous renal-replacement therapy (CRRT); no clinically significant drug–drug interactions are expected. The non-inferiority of cefiderocol versus high-dose, extended-infusion meropenem in all-cause mortality (ACM) rates at day 14 was demonstrated in the randomized, double-blind APEKS–NP Phase 3 clinical study in patients with nosocomial pneumonia caused by suspected or confirmed Gram-negative bacteria. …”
Get full text

Multi-component pharmacokinetics assessment of Artemisia annua L. in rats based on LC-ESI-MS/MS quantification combined with molecular docking by Chunqing Fu, Keyu Zhang, Manyuan Wang, Feng Qiu

“…The molecular docking results indicated that those flavonoids and coumarins of A. annua interacting with CYPs mainly through hydrogen bonding and π-π stacking had better CYP450 enzyme binding ability than the sesquiterpenoids, which were easier to induce drug interactions. This study presented an integrated strategy for investigating the pharmacokinetic behaviors of eight components in A. annua and laid the foundation for revealing the mechanism of action of A. annua in the organism.…”
Get full text

Shift from older‐ to newer‐generation antiseizure medications in people with acute ischemic stroke in Australia: A population‐based study by Stella Jung‐Hyun Kim, Stephen Wood, Clara Marquina, Emma Foster, J. Simon Bell, Jenni Ilomäki

“…This may lead to unnecessary exposure to adverse events and drug–drug interactions. Further research is needed to evaluate comparative effectiveness and safety of newer‐ and older‐generation ASMs in poststroke populations.…”
Get full text

Definition of self-medication: a scoping review by Daniela Baracaldo-Santamaría, Maria José Trujillo-Moreno, Andrés M. Pérez-Acosta, John Edwin Feliciano-Alfonso, Carlos-Alberto Calderon-Ospina, Franklin Soler

“…It represents a public health problem due to antibiotic resistance, risk of adverse drug reactions, drug–drug interactions, disease masking, and increased morbidity. …”
Get full text

Complementary and Alternative Medicine for Management of Premature Ejaculation: A Systematic Review by Katy Cooper, PhD, Marrissa Martyn-St James, PhD, Eva Kaltenthaler, PhD, Kath Dickinson, MA, Anna Cantrell, MA, Shijie Ren, PhD, Kevan Wylie, MD, Leila Frodsham, MBChB, MRCoG, Catherine Hood, BA, BMBCh (oxon)

“…There are sparse data on adverse effects or potential for drug interactions. Further well-conducted randomized controlled trials would be valuable.…”
Get full text

Healing Treatments in COVID-19 Patients: A Narrative Review by Thibault Sixt, Florian Moretto, Clementine Esteve, Michel Duong, Marielle Buisson, Sophie Mahy, Mathieu Blot, Lionel Piroth

“…Among direct antiviral treatments, ritonavir-boosted nirmatrelvir appears to currently be the cornerstone in the management of early infections, but its use may be limited by drug interactions. Remdesivir remains as an alternative in this situation, even though it is potentially less convenient. …”
Get full text

Heavily treatment-experienced people living with HIV in the OPERA® cohort: population characteristics and clinical outcomes by Ricky K. Hsu, Jennifer S. Fusco, Cassidy E. Henegar, Vani Vannappagari, Andrew Clark, Laurence Brunet, Philip C. Lackey, Gerald Pierone, Gregory P. Fusco

“…Abstract Background Multi-class resistance, intolerance, and drug–drug interactions can result in unique antiretroviral (ART) combinations for heavily treatment-experienced (HTE) people living with HIV (PLWH). …”
Get full text

Flavoured water consumption alters pharmacokinetic parameters and increases exposure of erlotinib and gefitinib in a preclinical study using Wistar rats by Aliyah Almomen, Hadir M. Maher, Nourah Z. Alzoman, Shereen M. Shehata, Amal Alsubaie

“…Therefore, ERL and GEF are candidates for drug-drug and food-drug interactions with a consequent effect on drug exposure and/or drug-related toxicities. …”
Get full text

Cenobamate significantly improves seizure control in intellectually disabled patients with drug-resistant epilepsy and allows drug load reduction by Anna-Lena Friedo, Benedikt Greshake, Konstantin L. Makridis, Konstantin L. Makridis, Konstantin L. Makridis, Konstantin L. Makridis, Hans-Beatus Straub

“…After more than 1 year of treatment with CNB, close monitoring and management of drug–drug interactions may reduce enzyme-inducing ASMs and lead to better long-term outcomes. …”
Get full text

Effectiveness and Safety of Oral Anticoagulants in Older Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis by Maxim Grymonprez, Stephane Steurbaut, Tine L. De Backer, Mirko Petrovic, Lies Lahousse, Lies Lahousse

“…In this vulnerable patient group, NOACs tend to be underused or underdosed due to concerns of excessive fall-related intracranial bleeding, cognitive impairment, multiple drug-drug interactions, low body weight or impaired renal function. …”
Get full text

Efficacy and safety of artemether-lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz-based antiretroviral therapy in Zambia: a... by Banda, C, Chaponda, M, Mukaka, M, Mulenga, M, Hachizovu, S, Kabuya, J, Mulenga, J, Sikalima, J, Kalilani-Phiri, L, Terlouw, D, Khoo, S, Lalloo, D, Mwapasa, V

“…Artemether-lumefantrine (AL) is the most commonly used ACT for treatment of falciparum malaria in Africa but there is limited evidence on the safety and efficacy of AL in HIV-infected individuals on ART, among whom drug-drug interactions are expected. Day-42 adequate clinical and parasitological response (ACPR) and incidence of adverse events was assessed in HIV-infected individuals on efavirenz-based ART with uncomplicated falciparum malaria treated with AL.…”

Indications for the measurement of plasma digoxin concentrations. by Aronson, J

“…The most important factors in the first category are renal impairment and drug interactions (particularly the interaction of digoxin with quinidine), although even in these circumstances the concentration/effect relationship may also be disturbed. …”

Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: the ARREST RCT by Thwaites, GE, Scarborough, M, Szubert, AJ, Concalves, P, Soares, M, Bostock, J, Nsutebu, E, Tilley, R, Cunningham, R, Grieg, J, Wyllie, SA, Wilson, P, Auckland, C, Cairns, J, Ward, D, Lal, P, Guleri, A, Jenkins, N, Sutton, J, Wiselka, M, Armando, G-R, Graham, C, Chadwick, PR, Barlow, G, Gordon, C, Young, B, Meisner, S, McWhinney, P, Price, DA, Harvey, D, Nayar, D, Jeyaratnam, D, Planche, T, Minton, J, Hudson, F, Hopkins, S, Williams, J, Torok, EM, Llewelyn, MJ, Edgeworth, JD, Walker, AS

“…The secondary endpoints will include all-cause mortality through 14 days; duration of bacteraemia; death or clinically defined treatment failure or disease recurrence by 12 weeks adjudicated by an independent endpoint committee blind to treatment allocation; the development of rifampicin resistant S. aureus; modification of any drug treatment due to drug interactions; and serious adverse events and reactions. …”

Efficacy and safety of dihydroartemisinin–piperaquine for treatment of Plasmodium falciparum uncomplicated malaria in adult patients on antiretroviral therapy in Malawi and Mozambi... by Sevene, E, Banda, C, Mukaka, M, Maculuve, S, Macuacua, S, Vala, A, Piqueras, M, Kalilani-Phiri, L, Mallewa, J, Terlouw, D, Khoo, S, Lalloo, D, Mwapasa, V

“…Dihydroartemisinin–piperaquine (DPQ) is recommended for treatment of <em>Plasmodium falciparum</em> malaria, but its efficacy and safety has not been evaluated in HIV-infected individuals on ART, among whom drug–drug interactions are expected. Day-42 adequate clinical and parasitological response (ACPR) and incidence of adverse events were assessed in HIV-infected individuals on non-nucleoside reverse transcriptase inhibitor-based ART (efavirenz and nevirapine) with uncomplicated <em>P. falciparum</em> malaria treated with dihydroartemisinin–piperaquine.…”

Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial by Thwaites, GE, Scarborough, M, Szubert, AJ, Nsutebu, E, Tilley, R, Greig, J, Wyllie, SA, Wilson, P, Auckland, C, Cairns, J, Ward, D, Lal, P, Guleri, A, Jenkins, N, Sutton, J, Wilselka, M, Armando, G-R, Graham, C, Chadwick, PR, Barlow, G, Gordon, NC, Young, B, Meisner, S, McWhinney, P, Price, DA, Harvey, D, Nayar, D, Jeyaratnam, D, Planche, T, Minton, J, Hudson, F, Hopkins, S, Williams, J, Torok, ME, Llewelyn, MJ, Edgeworth, JD, Walker, AS

“…From randomisation to 12 weeks, no evidence of differences in serious (p=0·17) or grade 3–4 (p=0·36) adverse events were observed; however, 63 (17%) participants in the rifampicin group versus 39 (10%) in the placebo group had antibiotic or trial drug-modifying adverse events (p=0·004), and 24 (6%) versus six (2%) had drug interactions (p=0·0005). <strong>Interpretation</strong> Adjunctive rifampicin provided no overall benefit over standard antibiotic therapy in adults with S aureus bacteraemia.…”

Utilization of non-steroidal anti-inflammatory drugs in orthopaedic ward at Ampang Hospital / Nur Aini Salamat by Salamat, Nur Aini

“…All potential drug-drug interactions with NSAIDs were involving diuretics and ACE Inhibitors. …”
Get full text